Combatting COVID-19 with a little brown pill
As pharmaceutical companies around the world race to combat the coronavirus (COVID-19) pandemic with vaccines more are focusing on antiviral treatments with Merck leading the race. With more than 200 antiviral pills in development, Merck is the furthest along with their antiviral drug molnupiravir currently in clinical trials.
A covid pill could be coming sooner than you think. Think Tamiflu for covid. If Merck's drug works, it could be a gamechanger in the fight against this ever-mutating virus. w/@rileyraygriffin in this week's @BW $MRKhttps://t.co/Z2OWPVBqQe
— Cynthia Koons (@CynthiaLKoons) March 25, 2021
If proven safe and approved for use, molnupiravir will be a vital tool for doctors to help combat COVID-19 that is being compared to the Tamiflu treatment for the common flu. Merck’s little brown pill is currently in mid-stage with their clinical study with plans for larger trials to determine whether it prevents severe illness and death.
Molnupiravir’s journey for approval started in January before targeting the medication to be used for COVID-19 seeking funding to progress flu studies and explore the use of treatment for Ebola. Shortly after the release of early data for molnupiravir, the world shut down with COVID-19 lockdowns beginning around the world.
A pill reduced infectious virus in Covid-19 patients in a mid-stage study. Larger trials are under way exploring whether it prevents severe illness and death. https://t.co/R8i7ssSyyn
— The Wall Street Journal (@WSJ) March 6, 2021
After news of a worldwide lockdown, the demand for the drug was established with clinical trials for the pill starting in April. By May, Merck & Co. acquired the rights to molnupiravir from the initial developer, Ridgeback, and initiated the beginning of large-scale trials that began in the fall to be authorized by regulators.
Merck might be further in development with competition but other competitors are also gaining traction in clinical trials including Pfizer. The U.S. drugmaker has already successfully gained approval for emergency use by the FDA for the vaccine and recently announced they will be moving forward with human trials for their antiviral treatment. Pfizer’s oral antiviral drug can be used at the first sign of illness to prevent viral replication that works similar to other treatment drugs for Hepatitis C and HIV.
-
White House Reveals Disturbing Executions and Threats in Conflict The White House has disclosed deeply concerning information regarding the...
-
Military Exercises Coincide with Treaty Developments Amid Global Concerns Russia recently executed a large-scale military exercise to rehearse its...
-
Company Addresses Auto-Translation Error Impacting Palestinian Users Meta, the parent company of Instagram, has issued a formal apology for...
-
China’s Ambitious Plans to Double Its Nuclear Warhead Stockpile Highlighted in Pentagon’s Annual Report The annual report released by...
-
Strengthening Partnerships and Providing Support in Challenging Times In a collaborative effort between the U.S. Congress and the White...
-
Humza Yousaf Extends Support and Sanctuary Amidst Gaza Conflict Humza Yousaf, the First Minister of Scotland, has extended a...
-
U.S. Stresses Peace and Humanitarian Aid in Israeli-Palestinian Conflict In an exclusive interview aired on Sunday, President Joe Biden...
-
Urgent Call for Aid as Communities Reel from Tremors The western province of Herat in Afghanistan has been rocked...
-
Calls for Peace Amid Diverse Perspectives on Ongoing Crisis In response to a series of recent demonstrations across Canada,...
-
Celebrity Voices in the Israel-Palestine Dialogue In the midst of the ongoing Israel-Palestine conflict, a group of celebrities has...
-
Devastating Loss of Lives Sparks Outrage and International Concern A devastating Russian attack on the peaceful village of Hroza,...
-
Dutch Research Organization’s Forecast Faces Skepticism from Scientists and Authorities Recent predictions by the Solar System Geometry Survey (SSGS),...